PMID- 36129571
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20230127
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Print)
IS  - 1523-3812 (Linking)
VI  - 24
IP  - 10
DP  - 2022 Oct
TI  - The Emerging Field of Psychedelic Psychotherapy.
PG  - 583-590
LID - 10.1007/s11920-022-01363-y [doi]
AB  - PURPOSE OF REVIEW: Few treatments are available for patients with mood disorders 
      or post-traumatic stress disorder (PTSD) who have already failed multiple 
      interventions. After several decades when research into psychedelics was 
      effectively halted by federal legislation, the past several years have shown the 
      re-emergence of thoughtful investigations studying the utility of compounds such 
      as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin. RECENT FINDINGS: 
      Several studies have coupled the safe administration of psychedelic compounds in 
      a controlled environment after several hours of preparation of study participants 
      and followed by multiple sessions to integrate the psychedelic experience. The 
      improvement participants experience appear related to the often profound 
      perspective changes experienced and seem unlike the improvements seen in the 
      currently available care paradigms. Studies cited include treatment resistant 
      depression, end of life despair, and PTSD. Psychedelic psychotherapy, a unique 
      remarriage of biological therapy and psychotherapy, has the potential to 
      transform mental health care.
CI  - (c) 2022. The Author(s).
FAU - Barber, Gregory S
AU  - Barber GS
AUID- ORCID: 0000-0002-6261-8098
AD  - Department of Psychiatry, University of Maryland Medical Center, Baltimore, MD, 
      USA.
FAU - Aaronson, Scott T
AU  - Aaronson ST
AD  - Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health 
      System, 6501 N. Charles Street, Towson, MD, USA. saaronson@sheppardpratt.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220921
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Hallucinogens/adverse effects/therapeutic use
MH  - Humans
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use
MH  - Psilocybin/therapeutic use
MH  - Psychotherapy
MH  - *Stress Disorders, Post-Traumatic/chemically induced/drug therapy
PMC - PMC9553847
OTO - NOTNLM
OT  - MDMA
OT  - Psilocybin
OT  - Psychedelic-assisted therapy
OT  - Psychedelics
OT  - Treatment resistant depression
COIS- Dr. Barber has no conflicts of interest to report.
EDAT- 2022/09/22 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/09/21
CRDT- 2022/09/21 11:16
PHST- 2022/08/10 00:00 [accepted]
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/09/21 11:16 [entrez]
PHST- 2022/09/21 00:00 [pmc-release]
AID - 10.1007/s11920-022-01363-y [pii]
AID - 1363 [pii]
AID - 10.1007/s11920-022-01363-y [doi]
PST - ppublish
SO  - Curr Psychiatry Rep. 2022 Oct;24(10):583-590. doi: 10.1007/s11920-022-01363-y. 
      Epub 2022 Sep 21.